Articles

This legal action follows an investigation by the Therapeutic Goods Administration

There will not be a decision announced on scheduling of alkyl nitrites on 29 November 2018. Further public consultation will be undertaken.

Joint media release between Australian Border Force and Therapeutic Goods Administration

The TGA has launched a web hub to help consumers and health professionals find information on transvaginal (urogynaecological) surgical mesh.

Today we celebrate the official launch of the TGA Facebook page

Our annual survey measures satisfaction with a range of services and activities including our role and performance

Apalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group

Consumers can now report dodgy ads for medicines and medical devices through a single online form

Information about influenza vaccines for use in 2018

In reference to the ABC’s Fact Check article “Will the move to make codeine prescription-only save a100 lives a year” the Therapeutic Goods Administration (TGA) would like to clarify:

The medicines’ regulator is not proposing and will not be stopping GPs from prescribing high dose opioids

The TGA has issued a discussion paper on the use and misuse of prescription strong opioids, such as oxycodone, and whether there is a need for specific regulatory responses

Information about the TGA operations over the 2015/16 Christmas/New Year period

Stage two report for the Review of Medicines and Medical Devices has been released

The Therapeutic Goods Administration has published an interim decision on a proposal to up-schedule codeine

The TGA has imposed two new conditions on the inclusion of the SynchroMed II Programmable Pump in the Australian Register of Therapeutic Goods

From 1 July 2015 commercial IVD medical devices will be monitored under the Regulatory Compliance Framework

From 1 July 2015, new guidance and forms for Additional trade names and Extensions of Indications applications will be available

Between 24 May and 16 June, the ACBPS, TGA and APVMA took part in an international crackdown on fake and illegal medicines

The TGA is aware of regulatory action undertaken by the US Food and Drug Administration (FDA) in relation to the Maquet manufacturing facility in Hudson, New Hampshire, USA

Next Tuesday we will be launching the new TGA Business Services site.

Undertaking to the Secretary of the Australian Government Department of Health given for the purposes of section 42YL of the Act